Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | TDP2 | O95551 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | ALPI | P09923 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917366 | 1.00 | CDC25B (0.56) | CDC25BMAPTMEN1KMT2ATP53 | |
| SCHEMBL1542903 | 1.00 | CDC25B (0.56) | CDC25BMAPTMEN1KMT2ATP53 | |
| SCHEMBL9857337 | 0.90 | CDC25B (0.47) | CDC25BMAPTMEN1KMT2ATP53 | |
| SCHEMBL1152737 | 0.86 | MAPT (0.44) | CDC25BMAPTMEN1KMT2ATP53 | |
| SCHEMBL8444855 | 0.86 | CDC25B (0.45) | CDC25BMAPTMEN1KMT2ATP53 | |
| SCHEMBL1152792 | 0.85 | MAPT (0.48) | CDC25BMAPTMEN1KMT2ATP53 | |
| SCHEMBL9856788 | 0.83 | CDC25B (0.45) | CDC25BMAPTMEN1KMT2ATP53 | |
| SCHEMBL8136452 | 0.83 | MAPT (0.51) | CDC25BMAPTMEN1KMT2ATP53 | |
| Buparvaquone SCHEMBL8200585 | 0.82 | CDC25B (0.66) | CDC25BMAPTMEN1KMT2ATP53 | |
| SCHEMBL9856931 | 0.82 | CDC25B (0.46) | CDC25BMAPTMEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6043286-A | COMBATTING WHITE FLY OR LEPIDOPTERA PESTS | BTG INTERNATIONAL LIMITED (GB) | 2000-03-28 | — | — | US | claimed |
| US-5310762-A | Medicaments | BURROUGHS WELLCOME CO. (US) | 1994-05-10 | — | — | US | claimed |
| EP-0362996-B1 | Naphthoquinones for the treatment and prophylaxis of pneumocystis carinii infections | WELLCOME FOUND (GB) | 1994-04-27 | — | — | EP | claimed |
| EP-0362996-A2 | Naphthoquinones for the treatment and prophylaxis of pneumocystis carinii infections | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-04-11 | — | — | EP | claimed |
| US-4485117-A | ANTIMALARIAL AND ANTICOCCIDIAL; HYDROXYNAPHTHOQUINONES | BURROUGHS WELLCOME CO., A CORP OF NORTH CAROLINA | 1984-11-27 | — | — | US | claimed |
| JP-2091037-A | — | — | None | — | — | JP | disclosed |
| JP-5097765-A | — | — | None | — | — | JP | disclosed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| WO-2012153162-A1 | NOVEL METHOD FOR PREPARATION OF ATOVAQUONE | LUPIN LIMITED (IN) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012153162-A1 | NOVEL METHOD FOR PREPARATION OF ATOVAQUONE | LUPIN LIMITED (IN) | 2012-11-15 | — | — | WO | disclosed |
| EP-2354987-A2 | METHOD FOR PREDICTING ACTIVATION ENERGY USING AN ATOMIC FINGERPRINT DESCRIPTOR OR AN ATOMIC DESCRIPTOR | Bioinformatics&Molecular Design Research Center (KR) | 2011-08-10 | — | — | EP | disclosed |
| EP-0362996-A2 | Naphthoquinones for the treatment and prophylaxis of pneumocystis carinii infections | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-04-11 | — | — | EP | disclosed |
| JP-H0291037-A | THERAPEUTIC AGENT | WELLCOME FOUND LTD:THE | 1990-03-30 | — | — | JP | disclosed |
| EP-0077551-B1 | 1.4-NAPHTHOQUINONES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL AND VETERINARY FORMULATIONS THEREOF | THE WELLCOME FOUNDATION LIMITED (GB) | 1985-06-12 | — | — | EP | disclosed |
| US-4485117-A | ANTIMALARIAL AND ANTICOCCIDIAL; HYDROXYNAPHTHOQUINONES | BURROUGHS WELLCOME CO., A CORP OF NORTH CAROLINA | 1984-11-27 | — | — | US | disclosed |
| US-4485117-A | ANTIMALARIAL AND ANTICOCCIDIAL; HYDROXYNAPHTHOQUINONES | BURROUGHS WELLCOME CO., A CORP OF NORTH CAROLINA | 1984-11-27 | — | — | US | disclosed |
| EP-0123239-A2 | Improvements in or relating to antiprotozoal agents | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-10-31 | — | — | EP | disclosed |
| EP-0077551-A2 | 1.4-Naphthoquinones, methods for their preparation, pharmaceutical and veterinary formulations thereof | THE WELLCOME FOUNDATION LIMITED (GB) | 1983-04-27 | — | — | EP | disclosed |
| EP-0077551-A2 | 1.4-Naphthoquinones, methods for their preparation, pharmaceutical and veterinary formulations thereof | THE WELLCOME FOUNDATION LIMITED (GB) | 1983-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | CDC25B 4385/4885MAPT 1583/4885MEN1 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.